Please use this identifier to cite or link to this item:
Title: Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus
Authors: Nicolas Salvadori
Bo Fan
Waralee Teeyasoontranon
Nicole Ngo-Giang-Huong
Siriluk Phanomcheong
Anita Luvira
Achara Puangsombat
Arunrat Suwannarat
Ussanee Srirompotong
Chaiwat Putiyanun
Tim R. Cressey
Luc Decker
Woottichai Khamduang
Linda Harrison
Camlin Tierney
John A. Shepherd
Athena P. Kourtis
Marc Bulterys
George K. Siberry
Gonzague Jourdain
Keywords: Medicine
Issue Date: 18-Jun-2019
Abstract: © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.
ISSN: 15376591
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.